|
|
|
|
Cell and gene therapy manufacturing is rapidly evolving, driven by market growth, scalable processes, automation, and digital innovation as developers seek efficient, reliable paths to commercialization.
|
|
|
|
|
Finding a CDMO partner with experience in cell therapy processes can help sponsor companies by offering flexible service at each level – pre-clinical through commercial – including specialized technical capabilities, equipment availability, facility design, and analytical platforms.
|
|
|
|
|
Early feasibility programs for gene therapy assess GOI compatibility, reduce development risks, prevent costly delays, and strengthen pathways to efficient, successful clinical manufacturing.
|
|
|
|
|
Platform-based manufacturing uses standardized, pre-qualified workflows and analytics that reduce variability, simplify regulatory submissions, and accelerate the path to commercial success.
|
|
|
|
|
Integrated AAV and LVV platforms streamline vector production, improving scalability, accelerating GMP readiness, and helping developers bring therapies to patients faster and more efficiently.
|
|
|
|
|
|
|
